source
- Roche stops two Huntington's disease gene-silencing programs after disappointing trial dataRoche announced it is ending development of two gene‑silencing candidates aimed at Huntington's disease after data failed to meet expectations. The decision follows a recent readout that showed in…
- ARPA-H awards $160 M to accelerate bespoke gene‑editing therapies for rare diseasesARPA-H announced a $160 million, five‑year investment through its THRIVE program to speed the development of personalized gene‑editing treatments for rare genetic conditions. The awardees include…